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Abstract
Universal newborn hearing screening (UNHS) is of paramount importance for early identification and management of
hearing impairment in children. However, infants with slight/mild, progressive, or late-onset hearing impairment might be
missed in conventional UNHS. To investigate whether genetic screening for common deafness-associated mutations could
assist in identifying these infants, 1017 consecutive newborns in a tertiary hospital were subjected to both newborn hearing
screening using a two-step distortion-product otoacoustic emissions (DPOAE) screening and newborn genetic screening
(NGS) for deafness. The NGS targeted 4 deafness-associated mutations commonly found in the Taiwanese population,
including p.V37I (c.109G.A) and c.235delC of the GJB2 gene, c.919-2A.G of the SLC26A4 gene, and mitochondrial
m.1555A.G of the 12S rRNA gene. The results of the NGS were then correlated to the results of the NHS. Of the 1017
newborns, 16 (1.6%) had unilateral DPOAE screening failure, and 22 (2.2%) had bilateral DPOAE screening failure. A total of
199 (19.6%) babies were found to have at least 1 mutated allele on the NGS for deafness, 11 (1.1%) of whom were
homozygous for GJB2 p.V37I, 6 (0.6%) compound heterozygous for GJB2 p.V37I and c.235delC, and 1 (0.1%) homoplasmic
for m.1555A.G, who may potentially have hearing loss. Among them, 3 babies, 5 babies, and 1 baby, respectively, passed
the NHS at birth. Comprehensive audiological assessments in the 9 babies at 3 months identified 1 with slight hearing loss
and 2 with mild hearing loss. NGS for common deafness-associated mutations may identify infants with slight/mild or
potentially progressive hearing impairment, thus compensating for the inherent limitations of the conventional UNHS.
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Introduction
Hearing loss is one of the most common congenital disorders,
with approximately 1 in 1000 newborns affected by bilateral
moderate, severe or profound (i.e. .40dBHL) permanent con-
genital hearing loss (PCHL) [1,2]. If the criterion of hearing loss is
lowered to 15 dBHL, 0.88% of the school-aged population have
slight or mild bilateral sensorineural hearing impairment (SNHI)
[3]. There is solid evidence that moderate (or more severe) hearing
impairment exerts a negative impact on speech, language, and
cognitive development [2], and early identification and manage-
ment may be of great benefit to these children, through improved
language, communication, mental health, and employment pro-
spects [4]. Although several risk factors (such as prolonged NICU
admission and congenital infections) are associated with PCHL,
about 50% of infants with PCHL do not have any known risk
factors [5,6], mandating the implementation of universal newborn
hearing screening (UNHS) for both newborns with and without
risk factors. The feasibility, cost-efficiency, and benefits of UNHS
were supported by several studies [1,7,8,9]. However, UNHS may
suffer from 3 inherent limitations. First, since the target condition
for the majority of UNHS programs is permanent hearing loss
.35 dBHL, children with slight or mild hearing loss will be missed
[10]. Second, children with late-onset or progressive hearing loss
may not be identified by UNHS, because their hearing is normal
or near-normal at birth. Third, even in countries where UNHS
has been implemented, it is difficult to approach and screen
specific subgroups of infants, such as those born outside of
hospitals [11].
With recent advancement in the molecular genetics of hearing
impairment, it has been demonstrated that more than 50% of
children with SNHI have attributable genetic factors [12], making
genetic testing a powerful tool for addressing hearing-impaired
children. Among a plethora of deafness genes discovered in the
past decade (The Hereditary Hearing Loss Homepage, http://
hereditaryhearingloss.org/), mutations in certain genes, such as
GJB2 (or Cx26) (MIM *121011), SLC26A4 (or PDS) (MIM
*605646), and the mitochondrial 12S rRNA gene (or MTRNR1)
(MIM *561000) have been shown to be much more prevalent than
other genes [13]. Some common GJB2 mutations, such as
p.M34T, p.V37I, and p.L90P are associated with mild-to-
moderate SNHI [14]. SLC26A4 mutations contribute to Pendred
syndrome (PS, MIM #274600) or non-syndromic hearing loss
(DFNB4, MIM #600791), and some affected patients have
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most common mitochondrial 12S rRNA mutation, m.1555A.G,
also demonstrate great variation in the severity of hearing loss
progression with age [18]. In other words, some common
deafness-associated mutations are associated with mild and/or
progressive hearing loss. Accordingly, in this study, we hypothesize
that the application of newborn genetic screening for common
deafness-associated mutations may compensate for the inherent
limitations of UNHS.
Methods
Recruitment and study design
From 2009 to 2010, 1017 consecutive newborns in the National
Taiwan University Hospital were enrolled in the study. All
newborns were subjected to both newborn hearing screening
(NHS) and newborn genetic screening (NGS) for deafness. The
results of the NGS were then correlated to the results of the NHS.
Written informed consent for participation in the project was
obtained from the parents of all infants, and all procedures were
approved by the Research Ethics Committee of the National
Taiwan University Hospital.
Newborn hearing screening
The babies received a two-step hearing screening using
distortion-product otoacoustic emissions (DPOAEs) recorded with
a GSI 60 DPOAE system (Grason-Stadler Inc., Milford, NH,
USA). The first step of the screening was performed at 48 hours
after birth to prevent debris and vernix in the external ear canal
from interfering with the DPOAE measurement [19]. Babies who
failed to pass the initial screening, either for one or for both ears,
were given a second chance to repeat the DPOAE screening
before they were discharged from the hospital. Those failing to
pass the second step of the hearing screening, either for one or for
both ears, were referred to the outpatient clinic for further
assessment. The referral rate of the NHS was determined by the
proportion of infants who failed both steps of the DPOAE
screening.
Newborn genetic screening for deafness
A bloodspot was obtained within 1 hour after birth. Sample of
blood from the heel stick from each infant was spotted onto
QIAcard FTA One Spot (Qiagen). For newborn screening, three
3-mm-diameter bloodspots from each blood spot on FTA paper
were punched out and used. All DNA samples were extracted
using the Chemagic DNA Blood Kit (Chemagen), according to the
manufacturer’s instructions.
Using our previously generated epidemiologic database [20],
the four most common deafness-associated mutations in the
Taiwanese population, p.V37I (c.109G.A) and c.235delC of
GJB2, c.919-2A.Go fSLC26A4, and mitochondrial m.1555A.G,
were included in the NGS panel. In terms of the allele frequency
in the hearing-impaired population, these 4 mutations amount to
.80% of the known deafness-associated mutations in Taiwanese
individuals [20,21].
The four mutations were screened using the real-time
polymerase chain reaction (PCR) assay with fluorescence reso-
nance energy transfer (FRET) hybridization probes in a Light-
Cycler 480 instrument (Roche) (Fig. 1). The real-time PCR was
performed using two primers and two adjacent fluorescent
hybridization probes. One probe was labeled with fluorescein at
the 39-end as the donor, and the other probe (acceptor) was
labeled with LightCycler (LC) Red fluorophore at the 59-end,
which was phosphorylated at the 39-end. Real-time PCR was
performed in a total volume of 10 mL containing 1 mL of DNA,
3 mM of MgCl2, 0.25 mM of each primer, 0.25 of mM fluorescein
probe, 0.25 mM of LC Red fluorophore probe, and 16 Light-
Cycler FastStart DNA Master Hybridization Probes Mix (Roche),
as provided by the manufacturer. The cycling conditions for real-
time PCR in LiC480 were as follows: 95uC for 10 min followed by
50 cycles of denaturation at 95uC for 10 s with a temperature
transition rate of 4.4uC/s, annealing at 56uC for 10 s with a
temperature transition rate of 2.2uC/s, and extension at 72uC for
10 s, with a temperature transition rate of 4.4uC/s.
Audiological assessments after discharge
For infants who failed the NHS, another DPOAE test was
performed within 1 month after discharge, and those failing to pass
the test again were referred to a pediatric otologist for com-
prehensive audiological assessments at 3 months. The compre-
hensive audiological assessments included a behavioral observa-
tion audiometry (BOA) in a sound field using warble tones, narrow
band noise, and live voice; DPOAE testing; and a diagnostic
auditory brainstem response (ABR, Nicolet, Bravo, Madison, WI,
USA) under sedation to determine the hearing thresholds at 0.5, 1,
2, and 4 kHz [22]. The hearing level of the better ear calculated
by four-tone average (0.5, 1, 2, and 4 kHz) was labeled as slight
(16,25 dBHL), mild (26,40 dBHL), moderate (41,70 dBHL),
severe (71,95 dBHL), or profound (.95 dBHL) (GENDEAF:
http://audiology.unife.it/www.gendeaf.org/index.html) [3].
For infants who passed the NHS but segregated for 2 mutated
GJB2 alleles (i.e., with the p.V37I/p.V37I, p.V37I/c.235delC, and
c.235delC/c.235delC genotypes), 2 mutated SLC26A4 alleles (i.e.,
with the c.919-2A.G/c.919-2A.G genotype), or the m.1555A.G
mutation (i.e., homoplasmicorheteroplasmic), comprehensiveaudio-
logical assessments including BOA, DPOAE, and ABR were also
performed at 3 months to confirm their audiological phenotypes.
Genetic examination in hearing impaired infants and
heterozygous infants
For hearing-impaired infants who revealed an inconclusive
genotype in NGS (i.e., segregating 0 or only 1 mutated GJB2 or
SLC26A4 allele), mutation screening of both exons of GJB2, all of
the 21 exons of SLC26A4, and the whole mitochondrial 12S rRNA
gene was completed by direct sequencing [20]. For infants who
passed the NHS but carried heterozygous GJB2 mutations, direct
sequencing of the coding region of GJB2 was also performed.
Results
Results of newborn hearing screening
Results of the two-step NHS in the 1017 subjects are
summarized in Table 1. Among the 1017 babies, 979 (96.3%)
were screened as normal when they bilaterally passed both steps of
the DPOAE testing. Of the remaining 38 babies, 16 (1.6%) had
unilateral DPOAE screening failure, and 22 (2.2%) had bilateral
DPOAE screening failure. The referral rate of the two-step NHS
was 3.7%.
Results of newborn genetic screening for deafness
Of the 1017 subjects, a total of 199 (19.6%) were screened as
having at least 1 mutated allele according to the NGS for deafness.
Table 2 summarizes their genotypes. As for the GJB2 mutations,
17 subjects (1.7%) had two mutated alleles, 11 (1.1%) of whom
were homozygous for p.V37I and 6 (0.6%) compound heterozy-
gous for p.V37I and c.235delC. None (0%) were homozygous for
c.235delC. Nineteen subjects (1.9%) were shown to have 1
c.235delC allele, and 156 subjects (15.3%) were heterozygous for
Newborn Genetic Screening for Deafness
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cohort was compatible to that observed in a normal control
population in our previous report [23]. In relation to the SLC26A4
c.919-2A.G mutation, 6 subjects (0.6%) were heterozygous for
c.919-2A.G and none (0%) were homozygotes. One subject
(0.1%) was found to have the m.1555A.G mutation, with the
mutation load detected as ‘‘homoplasmy’’ in hybridization probe
testing, which was later confirmed using a restriction enzyme
digestion method [24]. None of the 1017 babies segregated for
mutations in 2 different genes for deafness, according to NGS.
Analysis of NHS results according to genotypes in NGS
The results of NHS in subjects with different genotypes in NGS
are shown in Table 3. Among the 11 babies homozygous for the
GJB2 p.V37I mutation and the 6 babies compound heterozygous
for GJB2 p.V37I and c.235delC, 8 (73%) and 1 (17%), respec-
tively, failed to pass the NHS. In other words, 3 babies
homozygous for p.V37I and 5 babies compound heterozygous
for p.V37I and c.235delC, with potential hearing problems, were
Figure 1. Melting curve analysis of real-time hybridization with FRET probes for the four most common deafness-associated
mutations in the Taiwanese population. A, p.V37I of the GJB2 gene; B, c.235delC of the GJB2 gene; C, c.919-2A.G of the SLC26A4 gene; and D,
mitochondrial m.1555A.G.
doi:10.1371/journal.pone.0022314.g001
Table 1. Newborn hearing screening in the 1017 subjects.
OAE results No. of subjects (%)
Bilateral pass 979 (96.3)
Unilateral failure 16 (1.6)
Bilateral failure 22 (2.2)
Total 1017 (100)
Referral rate 38 (3.7)
doi:10.1371/journal.pone.0022314.t001
Table 2. Newborn genetic screening in the 1017 subjects.












No mutation identified 818 (80.4)
wt, wild type.
doi:10.1371/journal.pone.0022314.t002
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additional subgroup of affected newborns outside the target area of
NHS.
The failure rates of NHS in the 156 GJB2 p.V37I heterozygotes
and 19 c.235delC heterozygotes were 5% (n=8) and 5% (n=1),
respectively. Both exons of GJB2 were then sequenced in the 9
heterozygous babies who failed to pass NHS, yet we did not
identify any mutation in the second GJB2 allele. Likewise, a
second GJB2 mutation was not detected in the other 166
heterozygous babies who passed NHS, indicating that they were
probably coincidental carriers of the mutations.
None (0%) of the 6 babies heterozygous for SLC26A4 c.919-
2A.G failed to pass NHS. Probably these babies were only
carriers. However, the possibility of Pendred syndrome or non-
syndromic DFNB4 could not be completely excluded, because PS
or DFNB4 patients might be born with normal hearing or minimal
hearing loss, with their hearing deteriorating later during child-
hood or adolescence [25]. The only subject who was homoplasmic
for the mitochondrial m.1555A.G mutation passed the NHS,
implying that the hearing of this baby at birth might still be normal
or near normal and could not be detected by NHS.
Audiological assessments after discharge
Among the 38 infants who failed the NHS, 9 (24%) segregated
for 2 mutated GJB2 alleles (including 8 p.V37I homozygotes and 1
p.V37I/c.235delC compound heterozygote), 9 (24%) segregated
for 1 mutated GJB2 allele (including 8 p.V37I heterozygotes and 1
c.235delC heterozygote), and 20 (53%) segregated for none of the
4 deafness-associated mutations (Table 4). Six of the 9 babies with
2 mutated GJB2 alleles revealed bilateral hearing loss at 3 months,
including 2 with moderate hearing loss, 3 with mild hearing loss
and 1 with slight hearing loss. The other 3 babies with 2 mutated
GJB2 alleles revealed normal hearing at 3 months. Nevertheless, a
close observation of hearing is still warranted in these 3 babies
because progressive hearing loss is a common feature in patients
with p.V37I [26]. One of the 9 babies with 1 mutated GJB2 allele
demonstrated bilateral moderate hearing loss at 3 months, and 1
of the 20 babies with no mutation detected by NGS showed
unilateral profound hearing loss.
Comprehensive audiological assessments were also completed in
the 9 infants who passed the NHS but segregated for 2 mutated
GJB2 alleles or homoplasmic m.1555A.G mutation (Table 5).
One baby (NGS0071) showed slight hearing loss at 3 months,
whereas 2 babies (NGS0032 and NGS0379) showed mild hearing
loss at 3 months.
The clinical utility of NGS was summarized in the flow from
NHS and NGS to identification of hearing loss (Fig. 2). Among the
979 newborns who passed NHS, 9 were identified to have
potential hearing deficits by NGS. Of these 9, 3 were identified
with slight/mild hearing loss at 3 months with diagnostic ABR. In
other words, NGS might be useful for identifying slight/mild
hearing loss that was not detected by conventional NHS.
Genetic examination in hearing impaired infants
As shown in Table 4, 1 baby with bilateral moderate hearing
loss harbored only a mutated GJB2 allele, and 1 baby with
unilateral profound hearing loss had none of the 4 deafness-
associated mutations. Mutation screening of both exons of GJB2,
all 21 exons of SLC26A4, and the whole mitochondrial 12S rRNA
gene, was performed in the 2 babies, yet no mutation was
identified.
Discussion
In the present study, we developed a high throughput genetic
screening tool to screen 4 common deafness-associated mutations
in the Taiwanese population, and applied it to a prospective
cohort of 1017 newborns. Our preliminary results revealed that
NGS for deafness might compensate for the inherent limitations of
conventional UNHS, including failure to identify infants with
slight or mild hearing loss, as well as failure to identify infants who
may potentially have late-onset or progressive hearing loss during
childhood or adolescence.
There have been disputes with regard to whether the goal of
UNHS should be to find out infants with slight or mild hearing loss
[10,27]. Several studies demonstrated that slight/mild bilateral
SNHI might also have a negative impact on academic perfor-
mance [28], attention capacity [29], and language skills [30] of
children. In a study arguing that slight/mild bilateral SNHI might














p.V37I/p.V37I 11 3 8 73
p.V37I/c.235delC 6 5 1 17
p.V37I/wt 156 148 8 5
c.235delC/wt 19 18 1 5
SLC26A4
c.919-2A.G/wt 6 6 0 0
Mitochondrial 12S rRNA
m.1555A.G1 1 0 0
NHS, newborn hearing screening; wt, wild type.
doi:10.1371/journal.pone.0022314.t003
Table 4. Audiological results (at 3 m) in infants failing NHS.
Genotype Total (n) Loss F/U (n) Normal hearing (n) Unilateral (n) Bilateral (n)
2 mutated GJB2 alleles 9 0 3 0 6
a
1 mutated GJB2 allele 9 1 7 0 1
b
No mutation detected 20 3 16 1
c 0
aIncluding 2 babies with moderate hearing loss, 3 with mild hearing loss and 1 with slight hearing loss.
bThe baby revealed bilateral moderate hearing loss.
cThe baby revealed unilateral profound hearing loss.
doi:10.1371/journal.pone.0022314.t004
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life, phonological short-term memory and phonological discrim-
ination were reported to be poorer in children with slight/mild
bilateral SNHI [3]. However, including slight/mild losses within
the target population of UNHS indicates that the screening
program should be altered to achieve higher sensitivity, which
inevitably will reduce the specificity of UNHS and greatly increase
referral and false-positive rates [27]. To circumvent this difficulty,
efforts have been made to ascertain the risk factors for slight/mild
SNHI, disclosing that conventional risk factors for neonatal
hearing loss, such as craniofacial anomaly, family history of
childhood hearing loss and perinatal illness, were not strongly
predictive of slight/mild SNHI [31]. On the other hand, the
present study provides evidence that NGS, by detecting subjects
with genetic mutations associated with mild-to-moderate SNHI,
might help in identifying slight/mild SNHI not targeted by
conventional UNHS. Although there is still no unanimous
consensus concerning the standard management of infants with
Table 5. Audiological results (at 3 m) in infants passing NHS but segregating for an abnormal genotype.
ABR threshold (dBHL)
Subject no. Sex Genotype Laterality
DPOAE
results 0.5 k Hz 1 k Hz 2 k Hz 4 k Hz average
Audiometry
shape
NGS0032 M GJB2 p.V37I/c.235delC bil. symmetric bil. pass 25 30 30 30 28.8 flat
NGS0071 F GJB2 p.V37I/c.235delC bil. symmetric bil. pass 15 15 15 20 16.3 flat
NGS0072 F GJB2 p.V37I/p.V37I bil. symmetric bil. pass 15 10 15 15 13.8 flat
NGS0379 F GJB2 p.V37I/c.235delC bil. symmetric bil. pass 30 35 35 35 33.8 flat
NGS0586 F m.1555A.G bil. symmetric bil. pass 15 10 10 15 12.5 flat
NGS0598 F GJB2 p.V37I/c.235delC bil. symmetric bil. pass 10 10 10 15 11.3 flat
NGS0736 M GJB2 p.V37I/p.V37I bil. symmetric bil. pass 10 5 5 10 7.5 flat
NGS0830 F GJB2 p.V37I/c.235delC bil. symmetric bil. pass 10 10 10 10 10 flat
NGS0961 M GJB2 p.V37I/p.V37I bil. symmetric bil. pass 10 10 5 10 8.75 flat
doi:10.1371/journal.pone.0022314.t005
Figure 2. From newborn hearing screening (NHS) and newborn genetic screening (NGS) to identification of hearing loss. Among the
979 newborns who passed NHS, 9 were identified to have potential hearing deficits by NGS. Of these 9, 3 were identified with slight/mild hearing loss
at 3 months with diagnostic ABR. ABR, auditory brainstem response.
doi:10.1371/journal.pone.0022314.g002
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language monitoring, and provision of resources to parents are
recommended [32,33]. Infants diagnosed as having slight/mild
SNHI in the present cohort were referred to rehabilitation facilities
for further consultation with an audiologist and a speech
pathologist. Even if parents chose not to have their baby fit with
a hearing aid immediately, they were provided with information
about how to optimize the listening environment for their baby.
To identify infants and children with late-onset or progressive
hearing loss at the earliest possible time is also considered
important and has been included in the national Early Hearing
Detection and Intervention (EHDI) goals (http://www.cdc.gov/
ncbddd/ehdi/nationalgoals.htm). However, there is still no
efficient way to achieve this goal [11]. In a recent report,
progressive hearing impairment was noted in 7 (39%) of the 18
patients who were either homozygous for p.V37I mutation or
segregated for a p.V37I allele in compound heterozygosity with a
truncating allele, indicating that progression is a common feature
for p.V37I [26]. In a Japanese cohort, it was also reported that
p.V37I was found mainly in patients diagnosed at a higher age
[34]. Progressive hearing loss has also been reported among
patients with other GJB2 mutations, such as p.M34T [35,36].
These lines of evidence highlight the clinical utility of NGS for
certain GJB2 mutations in identifying infants who are likely to
have late-onset or progressive hearing loss, necessitating a close
observation of hearing in these affected individuals. The potential
benefits of identifying subjects with SLC26A4 mutations or the
mitochondrial m.1555A.G mutation might even be greater. For
subjects with SLC26A4-mutation-associated Pendred syndrome or
non-syndromic DFNB4, attacks of acute sensorineural hearing loss
could be prevented by avoiding head trauma or abrupt barometric
pressure changes [25], thus halting the progression or fluctuation
of hearing impairment. The severity of hearing loss due to
m.1555A.G mutation is modulated by several factors [24].
Especially, the use of aminoglycosides should be avoided in
individuals with the mutation, because m.1555A.G is well
established as a predisposing factor for aminoglycoside ototoxicity
[37].
Interestingly, a recent study reported 32 of 108 cochlear implant
(CI) recipients (29.6%) born in Illinois during or after 2003 passed
UNHS, demonstrating the limitation of the current UNHS in
early identification of delayed-onset SNHI [38]. The authors also
pointed out that this problem could not be solved by recent JCIH
guidelines, which suggest reevaluation by 24 to 30 months of age
in children with known risk factors who pass UNHS [38].
Repeated hearing screening in all children provides a solution, but
it might be rather costly as well as unfeasible once the babies are
discharged from hospitals or clinics. On the other hand, NGS
might be helpful in identifying a group of children with increased
risk in developing SNHI for whom a close audiological assessment
should be implemented. In the Illinois series, a substantial
proportion of CI recipients would have been identified by NGS,
since among the 32 CI recipients who passed UNHS, 6 were
diagnosed as having connexin mutations, and 7 were found to
have cochlear malformations, which might be associated with
SLC26A4 mutations.
With regard to the difficulty in approaching and screening
specific subgroups of infants such as those born outside of
hospitals, NGS might also serve as an alternative solution.
Obtaining a few drops of blood from a heel stick within the first
2 or 3 days of life is a minimally invasive procedure, and can be
conducted by a nurse or a midwife with basic training. In addition,
the new generation of DNA cards, such as filter blotters, Guthrie
cards, and FTA cards, are easy to collect, transport, and store.
Offering parents reproductive choices (prenatal diagnosis) has
been considered a benefit of expanded newborn screening
programs [39]. Although this might be true for certain rare
diseases, its clinical implications in deafness should be scrutinized
with caution. Some deaf advocates argue that deafness is not a
disability, and are against screening for hearing defects [40]. Even
for hearing parents of deaf children, it has been documented that
few of them would use genetic information to terminate an
affected pregnancy, although most recorded a positive attitude
toward prenatal genetic testing for deafness [41,42].
New ethical questions might emerge with the institution of NGS
for deafness, including risks of discrimination or stigmatization,
respect for autonomy of persons to make their own decisions, and
parental anxiety resulting from a false positive test or the carrier
status of a recessive mutation, as other newborn screening panels
[39]. For hereditary hearing impairment, of which the majority of
cases are inherited in an autosomal recessive manner, identifica-
tion of healthy carriers could be of special concern because it
might lead to unjustified parental anxiety about the health of their
baby [43]. In the present study, 175 babies were found to carry 1
GJB2 mutation, and 6 babies were found to carry 1 SLC26A4
mutation; among them, 9 babies and no baby failed the NHS at
birth, respectively. These 9 babies were managed as other
newborns who failed the NHS according to the national
guidelines, i.e., another DPOAE test within 1 month after
discharge, followed by comprehensive audiological assessments
at 3 months if indicated. Seven of the 9 babies had normal hearing
at 3 months (Table 4), and were regarded as coincidental carriers,
given the high frequency of the GJB2 p.V37I allele in the
Taiwanese population and the absence of a second GJB2 mutation
in these babies. One baby revealed bilateral moderate hearing loss
at 3 months, and genetic counseling was performed as hearing-
impaired patients with only 1 GJB2 mutated allele detected [44].
By contrast, for carriers who passed the NHS, no further
audiological studies were performed. The great majority of these
babies were p.V37I heterozygotes, and were regarded as
coincidental carriers given the high frequency of the GJB2
p.V37I allele in the Taiwanese population. The parents were
assured that their babies were not at an increased risk of
developing hearing impairment, and access to genetic counseling
was provided whenever necessary to minimize potential stress for
families.
Of special note, deafness-associated mutations should be
adjusted if NGS for deafness is to be implemented in other
populations because different ethnic groups show different
mutation spectra for each deafness gene. Although mutations of
the connexin 26-encoding GJB2 gene are the most common cause
of hereditary hearing loss in most world populations, they occur at
different frequencies across populations. To screen GJB2 muta-
tions in Caucasians, c.35delG, p.M34T, and p.L90P should be
included in the screening panel instead of p.V37I and c.235delC,
since these mutations are more common in Caucasians [14].
Likewise, to screen GJB2 mutations in Ashkenazi Jews, c.167delT
should be included [45]. Leading to Pendred syndrome, the most
common form of syndromic deafness [46], as well as to DFNB4, a
common form of non-syndromic deafness with enlarged vestibular
aqueduct (EVA), mutations of SLC26A4 might be the second most
frequent cause of hereditary hearing loss worldwide. Common
SLC26A4 mutations also differ across populations. To screen
SLC26A4 mutations, p.T416P and c.1001+1G.A should be
covered in populations of northern European ethnicity
[47,48,49,50], whereas p.H723R should be included if screening
is to be performed in Japanese [51] or Koreans [52]. The
m.1555A.G mutation appears to be a common cause of hearing
Newborn Genetic Screening for Deafness
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sensorineural hearing-impaired Caucasians [53,54], Japanese
[55], and Southeast Asians [56]. In a European birth cohort
unselected for hearing loss, the prevalence of m.1555A.G was as
high as 1 in 520 [57], attesting to the necessity for conducting
national genetic screening prior to aminoglycoside administration.
For Spanish subjects, the p.Q829X mutation of the OTOF gene
(MIM *603861) should be added due to its high prevalence in
patients with prelingual SNHI [58].
Some limitations of the present study deserve discussion. First,
only common, known deafness-associated mutations are included
in the current screening panel. This might lead to a false assurance
in individuals with rare or novel mutations because of normal
NGS results. This limitation, however, might be overcome with
the advent of the next-generation sequencing technology, as
massively parallel sequencing has recently been proven as an
effective tool for addressing hereditary hearing loss [59]. Second,
as a preliminary report, the present study documented the
audiological results in 9 infants passing NHS, but segregating for
an abnormal genotype, until 3 months. Although 3 of them were
confirmed as having slight/mild SNHI, the follow-up period of 3
months is apparently too short to elucidate the frequency of late-
onset hearing loss. Long-term follow-up of the present cohort is
thus necessary to delineate correlations between NHS and NGS
findings. Third, genetic heterogeneity of hereditary hearing loss
might preclude a precise interpretation of NGS results. For
instance, genetic diagnosis is complicated by the fact that 10%–
50% of affected subjects with GJB2 mutations carry only 1 mutant
allele. Although the del(GJB6-D13S1830) mutation, through
eliminating a cis-regulatory element of GJB2, provided an
explanation for the deafness in as many as 30%–70% of affected
GJB2 heterozygotes in some populations [60,61], the etiology
remained unclear for the others. These affected heterozygotes pose
a diagnostic dilemma: their hearing loss might be attributed to an
unrecognized GJB2 mutation, or they might be merely coinci-
dental carriers with hearing loss unrelated to GJB2. Similarly, it is
also difficult to interpret the genetic results in babies who passed
NHS and segregated only 1 mutated GJB2 allele on NGS,
although it can be inferred that a greater proportion of these
babies are coincidental carriers as compared to ‘‘affected’’
heterozygotes. Nonetheless, NGS for deafness is still useful in
identifying babies with 2 mutated GJB2 alleles, for whom the
genetic diagnosis is more straightforward. These babies require a
close audiological observation or intervention because their
genotypes are associated with mild-to-moderate, progressive, or
late-onset hearing impairment.
In a retrospective report, it was demonstrated that some patients
with 2 GJB2 mutations could not be identified with UNHS [62].
By contrast, the present study might be the first prospective study
to have conducted hearing screening in conjunction with genetic
screening in all newborns and longitudinal follow-up of these
infants. For babies with a definite genetic diagnosis on NGS (i.e.,
with 2 mutated GJB2 alleles, 2 mutated SLC264 alleles,
homoplasmic or heteroplasmic m.1555A.G mutation) who reveal
normal hearing at 3 months, comprehensive audiological
evaluation will be repeated at 1 year, whereas for normal hearing
babies with 1 mutated GJB2 or SLC264 allele, adequate genetic
counseling will be implemented, and additional genetic study (such
as sequencing of the whole gene) will be provided whenever
necessary. Once hearing impairment develops in these babies, the
management protocol will be switched to the conventional
management protocol for pediatric SNHI regardless of their
genotypes. Long-term follow-up of this cohort might provide
insight into how and to what extent genetic mutations exert their
influence on the development of pediatric hearing impairment, as
well as provide important audiological information about the
natural history of specific genetic mutations, such as the GJB2
p.V37I mutation.
In conclusion, the present study revealed that NGS for common
deafness-associated mutations, by detecting subjects with muta-
tions associated with mild-to-moderate, progressive, or late-onset
hearing impairment, might compensate for the inherent limita-
tions of conventional UNHS (Fig. 3). For infants born outside of
hospitals and who do not have access to UNHS at birth, NGS
might also serve as an alternative. The benefits of NGS for
deafness would be maximized with the construction of a well-
designed infrastructure to support testing, counseling, education,
treatment, and follow-up. Despite its clinical utility, the authors
would like to emphasize that the role of NGS for deafness is to
augment the armamentarium of UNHS instead of replacing
UNHS, given that a genetic cause could not be identified in many
hearing-impaired children. To our knowledge, this pilot report
might be among the first to demonstrate the clinical utility of NGS
for deafness. A nation-wide screening is currently underway to
confirm the long-term benefits of NGS for the detection of
deafness.
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Figure 3. Clinical utility of newborn genetic screening (NGS) for
deafness. NGS for common deafness-associated mutations, by
detecting subjects with mutations associated with mild-to-moderate,
progressive, or late-onset hearing impairment, may compensate for the
inherent limitations of conventional universal newborn hearing
screening (UNHS), including failure to identify infants with slight or
mild hearing loss, as well as failure to identify infants who potentially
have late-onset or progressive hearing loss during their childhood or
adolescence. For infants born outside of hospitals and who do not have
an access to UNHS at birth, NGS may also serve as an alternative. SNHI,
sensorineural hearing impairment.
doi:10.1371/journal.pone.0022314.g003
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